Azzet reports on three stocks with price moving updates today.
Deep Yellow falls after posting dismal H1 loss ~
Shares in Deep Yellow (ASX: DYL) were trading 11% lower by 2:20 pm AEDT (3:20 am GMT) after the struggling uranium miner’s dismal 1H FY26 result added to growing market concerns.
After combating depressed uranium prices, leadership uncertainty, and its lack of active production compared to its peers, management today reported a half-year net loss of $7.78 million for the six months to December 31, 2025, widening from a $2.47 million loss in the prior corresponding period.
Today’s market update follows the miner’s brief trading halt yesterday as it prepared a response to speculation about a potential capital raise.
Revelations that the company was not, contrary to media speculation, planning to raise a whopping $2 billion saw the share price jump by around 3.5% yesterday.
Given the headwinds facing the stock, the market clearly was relieved to discover that media reports of an imminent capital raise were seemingly unfounded.
The stock was nudging the $3 a share level late January after some brokers lifted their long-term price forecast for uranium into the 2030s by 22% to US$110/lb.
However, the stock plunged to $2.20 a week later and has gone nowhere since.
Today’s 1H FY26 result did little to staunch negative market sentiment towards the stock.
Other key numbers announced today include:
- Total comprehensive loss, after a $6.95 million gain from foreign currency translation, was $826,000.
- Operating cash outflows grew to $2.55 million from $103,000 a year earlier.
- Revenue was $4 million for the half compared to $6.92 million in the previous period.
- Cash and cash equivalents ended the period at $187.2 million, down from $217.4 million at July 1, 2025.
The stock’s recent numbers have clearly led the market to question the miner’s pursuit of a 'dual pillar growth strategy’ designed to establish itself as a globally diversified, tier-1 uranium producer.
Looking forward, management told the market that Deep Yellow remains focused on de-risking and advancing its flagship Tumas Project, Namibia, toward readiness for development, supported by ongoing detailed engineering and early works.
The Company also continues to progress the Mulga Rock Project (MRP) in WA DFS, as well as further drilling at its Alligator River Project (ARP) in the Northern Territory and other exploration assets targeting a material increase in uranium mineral resources.
The Company’s strong cash position and two advanced projects ensure it is well positioned to capitalise on a strengthening uranium market.
Deep Yellow has a market cap of $2.2 billion; the share price is up 120% in one year and down 13% in the last week.
The stock appears to be in a long-term uptrend because its 200-day moving average is upward sloping and shows that there has been overall investor demand for the stock.
However, the stochastic oscillator is falling and indicates that there is some selling pressure.
Consensus is Moderate Buy.
Viking Mines jumps after updating on Linka
Shares in Viking Mines (ASX: VKA) were trading 10.5% higher after the gold-focused small cap miner identified significant priority exploration targets at its Linka tungsten project, Nevada.
On the heels of recent positive metallurgical results and a supportive tungsten price environment, today’s update follows phase one geophysical surveys, including an 820m mineralised corridor, and has expanded into phase two exploration.
This corridor extends for around 800m beneath southwest volcanic cover, suggesting a substantial hidden prospect.
By expanding its exploration efforts into phase two, the miner hopes to generate further high-priority targets.
The magnetic survey coverage has been extended by around 2.8 square kilometres to the west, while the gravity survey has been broadened by 0.35 square kilometres to the southwest.
The miner expects to initiate field validation by mid-March, which then sets the stage for potential drilling.
The initial survey program included 2.2 square kilometres of high-resolution ground magnetics and 0.5 square kilometres of high-resolution ground gravity, comprising 726 gravity stations and 111 line kilometres of magnetics.
Commenting on today’s update, Viking Mines CEO Julian Woodcock told the market that preliminary data provide greater clarity on geological contacts where mineralisation occurs, and potential direct priority targets where we see gravity high anomalies.
“The occurrence of gravity highs coincident with areas of known mineralisation at Linka Main and Conquest demonstrates that the technique can resolve areas of increased density. We can now use this methodology to generate additional targets across the Project for further evaluation,” he said.
“Coupled with high tungsten prices of US$1,850/mtu of APT, we are advancing the Project rapidly on multiple fronts with the aim of supporting the USA supply needs of this critical mineral."
Woodcock believes Viking is well-positioned to help ease the supply constraints for tungsten in the U.S. by swiftly moving Linka towards production.
“Our goal is the quickest development pathway to capitalise on high prices and US support for critical minerals,” he recently told investors.
Viking Mines has a market cap of $48 million; the share price is up 150% in one year and up 81% in the last month.
The stock appears to be in a strong bullish trend, confirmed by multiple indicators.
Specifically, a 5-day moving average of the stock price is above the 20 and 50-day moving averages.
Consensus does not cover this stock.
Alcidion Group jumps on broker upgrade
Shares in Alcidion Group (ASX: ALC) were trading 3% higher this afternoon after Moelis (MA Financial) initiated coverage on the healthcare software small cap with a Buy rating today.
What has attracted the broker to Melbourne-based Alcidion is the company's strong momentum in recurring revenue and recent major contract wins.
Major contract wins, including the expansion of Leidos Australia, were reflected in Alcidion’s 1H FY26 result (posted 26 February), which showed a 675% increase in underlying EBITDA to $4.2 million.
Much of the company’s strongest financial performance to date was underpinned by an accelerating annual rate of return (ARR) growth.
In the last 18 months, the company has signed over $97 million in contract value with generally 3, 5 or 10-year contract terms, which Moelis expects to solidify its ARR base for years to come.
Management also reconfirmed FY26 revenue guidance, which is expected to exceed $50.0 million with earnings in excess of $5.0 million, while operating cashflow is expected to remain in-line with FY25 operating cashflow of $5.8 million.
Commenting on the recent 1H result, Alcidion CEO Kate Quirke told the market that the company has a clear go-to-market proposition, which is increasingly resonating with both new and existing customers.
“We have broadening referenceabilty across all our core markets with our solutions addressing the major challenges being faced by the acute healthcare market, notably patient flow, integrated care records, virtual care, modular EPR, operations centre oversight and clinical workflows,” she said.
“We start the second half with FY26 contracted revenue at $43.1M, excluding any revenue contribution from UHSussex and with six months still remaining in this financial year.”
During the first half, Alcidion expanded its relationship with Leidos Australia, committing to deliver a comprehensive healthcare solution for critical care to the Australian Defence Force.
This is the third expansion to its original agreement and will see Miya Precision’s capability deployed across a wider scope of care settings and environments.
Given the scale of the overall project, Quirke believes the company’s expanding role adds to the value proposition of Miya Precision as a critical enterprise platform with the ability to share and interpret data via meaningful analytics and dashboards.
Key numbers announced today include:
- ARR as at 31 December 2025 of $31.1 million, up 9.1% from 30 June 2025.
- 1 FY26 new sales and renewals TCV of $23.6 million, driven by flagship customer expansions.
- Cash balance of $14.2 million and no debt as of 31 December 2025.
- FY26 contracted (sold and renewal) revenue of $43.1 million, up 40% on pcp.
In light of several material contract wins and with a clear focus on accelerating new sales in both existing and new markets, the company is incrementally investing in key areas of product delivery, sales and marketing to support deployment capability and pipeline conversion.
To the uninitiated, Alcidion Group offers a complementary set of software products and technical services that create a unique offering in the global healthcare market.
Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care.
Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned.
Alcidion Group has a market cap of $147 million; the share price is up 32% in one year and up 4.7% in the last week.
The stock’s shares appear to be in a near-term downtrend, confirmed by its 20-day moving average.
Specifically, the 20-day moving average is falling and implies that investors see better opportunities elsewhere.
Consensus is Moderate Buy.
This article does not constitute financial or product advice. You should consider independent advice before making financial decisions.
